Emerging drugs in cutaneous T-cell lymphomas

Bibliography

• WILLEMZE R, JAFFE ES, BURG G et al: WHO-EORTC classification for cutaneous lymphomas. Blood (2005) (in press).
   Google Scholar
• •Very import publication that introduces the worldwide accepted classification for primary cutaneous T-cell lymphomas.
   Google Scholar
• BEKKENK MW, GEELEN FA, VAN VOORST VADER PC et al: Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood (2000) 95(12):3653–3661.
   PubMed Web of Science ®Google Scholar
• VONDERHEID EC, BERNENGO MG, BURG G et al: Update on erythrodermic cutaneous T-cell lymphoma: report of The International Society for Cutaneous Lymphomas. J. Am. Acad. Dermatol. (2002) 46(1):95–106.
   PubMed Web of Science ®Google Scholar
• •This paper defines the criteria for the diagnosis of SS.
   Google Scholar
• KAYE FJ, BUNN PJ, STEINBERG SM et al: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N EngL J. Med. (1989) 321(26):366–372.
   Web of Science ®Google Scholar
• DUMMER R, KEMPF W, HESS SCHMID M, HAFFNER A, BURG G: Therapy of cutaneous lymphoma - current practice and future developments. Onkologie (2003) 26(4):1784–1790.
   Web of Science ®Google Scholar
• DUMMER R, DOBBELING U, GEERTSEN R, WILLERS J, BURG G, PAVLOVIC J: Interferon resistance of cutaneous T-cell lymphoma-derived clonal T-helper 2 cells allows selective viral replication. Blood (2001) 97:523–527.
   PubMed Web of Science ®Google Scholar
• ZHANG C, DUVIC M: Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma. Dermatol. Ther. (2003) 16(0322–330.
   PubMedGoogle Scholar
• ZHANG C, HAZARIKA P, NIX, WEIDNER DA, DUVIC M: Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin. Cancer. Res. (2002) 8(5):1234–1240.
   PubMed Web of Science ®Google Scholar
• DUVIC M, MARTIN AG, KIM Y et al: Phase II and III clinical trial of oral bexarotene (targeting capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch. Dermatol. (2001) 137(5):581–593.
   Google Scholar
• DUVIC M, HYMES K, HEALD P et al: Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational Phase II - III trial results. J. Clin. OncoL (2001) 19(9):2456–2471.
   PubMed Web of Science ®Google Scholar
• HEALD P, MEHLMAUER M, MARTIN AG, CROWLEY CA, YOCUM RC, REICH SD: Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the Phase III clinical trial. J. Am. Acad. Dermatol. (2003) 49(5): 801–815.
   PubMed Web of Science ®Google Scholar
• APISARNTHANARAX N, TALPUR R, WARD S, NIX, KIM HW, DUVIC M: Tazarotene 0.1% gel for refractory mycosis fungoides lesions: an open-label pilot study. J. Am. Acad. Dermatol. (2004) 50(4):600–607.
   PubMed Web of Science ®Google Scholar
• MARKS PA, RICHON VM, MILLER T, KELLY WK: Histone deacetylase Inhibitors. Adv. Cancer. Res. (2004) 91:137–168.
   PubMed Web of Science ®Google Scholar
• •Important introduction to HDACs.
   Google Scholar
• BAYES M, RABASSEDA X, PROUS JR: Gateways to clinical trials. Methods Find Exp. Clin. PharmacoL (2004) 26(5):357–391.
   PubMed Web of Science ®Google Scholar
• WOLLINA U, DUMMER R, BROCKMEYER NH et al: Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer (2003) 98(5):993–1001.
   PubMed Web of Science ®Google Scholar
• •Interesting study on the efficacy of pegylated liposomal doxorubicin in CTCL.
   Google Scholar
• OLSEN E, DUVIC M, FRANKEL A et ell.: Pivotal Phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J. Clin. OncoL (2001) 19(2):376–388.
   PubMed Web of Science ®Google Scholar
• LUNDIN J, HAGBERG H, REPP R et al: Phase II study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood (2003) 101(10:4267–4272.
   PubMed Web of Science ®Google Scholar
• LENIHAN DJ, ALENCAR AJ, YANG D, KURZROCK R, KEATING MJ, DUVIC M: Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood (2004) 104(3):655–658.
   PubMed Web of Science ®Google Scholar
• KENNEDY GA, SEYMOUR JF, WOLF M et al: Treatment of patients with advanced mycosis fungoides and Sezary syndrome with alemtuzumab. Eur. J. HaematoL (2003) 71(4):250–256.
   PubMed Web of Science ®Google Scholar
• BARTH S, HUHN M, MATTHEY B et al: Ki-4(Scfv)-eta', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood (2000) 95(12):3909–3914.
   PubMed Web of Science ®Google Scholar
• ASADULLAH K, DOCKE WD, VOLK HD, STERRY W: Cytokines and cutaneous T-cell lymphomas. Exp. Dermatol. (1998) 7(6):314–320.
   PubMed Web of Science ®Google Scholar
• VONDERHEID EC, BIGLER RD, GREENBERG AS, NEUKUM SJ, MICAILY B: Extracorporeal photopheresis and recombinant interferon alfa 2b in Sezary syndrome. Use of dual marker labeling to monitor therapeutic response. Am J. Clin. Oncol. (1994) 17(3):255–263.
   PubMed Web of Science ®Google Scholar
• DUMMER R, HEALD PW, NESTLE FO et al: Sezary syndrome's T-cell clones display T helper 2 cytokines and express the accessory factor-1 (interferon gamma receptor beta chain). Blood (1996) 88: 1383–1389.
   Google Scholar
• •Detection of Th2 cytokines in Sézary derived T-cell clones.
   Google Scholar
• UROSEVIC M, WILLERS J, MUELLER B, KEMPF W, BURG G, DUMMER R: HLA-y protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas. Blood (2002) 99(2):609–617.
   PubMed Web of Science ®Google Scholar
• DE VRIES JE: Immunosuppressive and anti-inflammatory properties of interleukin 10. Annals Of Medicine (1995) 27(5):537–541.
   PubMed Web of Science ®Google Scholar
• MOORE KW, O'GARRA A, DE WAAL R, VIEIRA P, MOSMANN TR: Interleukin-10. Ann. Rev. ImmunoL (1996) 135(4):572–575.
   Google Scholar
• ROMAGNANI S: Human Thl and Th2 subsets: regulation of differentiation and role in protection and immunopathology. Int. Arch. Allergy ImmunoL (1992) 98(4):279–285.
   PubMed Web of Science ®Google Scholar
• DUMMER R, LAINE E, DOBBELING U, BURG G, NESTLE F: T-cell relevant cytokines during extracorporeal photopheresis (ECP) in Sezary syndrome, detetcted by a newly developed PCR-ELISA technique. J. Invest. Dermatol. (1995) 104:653.
   Web of Science ®Google Scholar
• DUMMER R, KOHL O,, GILLISSON J, KAGI M, BURG G: Peripheral blood mononuclear cells in non-leukemic cutaneous T-cell lymphoma patients: reduced proliferation and preferential secretion of a T helper 2 like cytokine pattern on stimulation. Arch. Dermatol. (1993) 129:433–436.
   PubMed Web of Science ®Google Scholar
• STANLEY MA: Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin. Exp. Dermatol. (2002) 27(7):571–577.
   PubMed Web of Science ®Google Scholar
• HEMMI H, KAISHO T, TAKEUCHI O, et al.: Small anti-viral compounds activate immune cells via the TLR7 Myd88-dependent signaling pathway. Nat. ImmunoL (2002) 3(2):196–200.
   PubMed Web of Science ®Google Scholar
• HENGGE UR, BENNINGHOFF B, RUZICKA T, GOOS M: Topical immunomodulators-progress towards treating inflammation, infection, and cancer. Lancet Infect. Dis. (2001) 1(3):189–198.
   PubMedGoogle Scholar
• SUZUKI H, WANG B, SHIVJI GM et al.: Imiquimod, a topical immune response modifier, induces migration of langerhans cells. J. Invest. Dermatol. (2000) 114(1):135–141.
   PubMed Web of Science ®Google Scholar
• SUCHIN KR, JUNKINS-HOPKINS JM, ROOK AH: Treatment of stage Ia cutaneous T-cell lymphoma with topical application of the immune response amodifier imiquimod. Arch. Dermatol (2002) 138(9):1137–1139.
   PubMed Web of Science ®Google Scholar
• DUMMER R, UROSEVIC M, KEMPF W, KAZAKOV D, BURG G: Imiquimod induces complete clearance of a puva-resistant plaque in mycosis fungoides. Dermatology (2003) 207(1):116–118.
   PubMed Web of Science ®Google Scholar
• CHONG A. LOO WJ, BANNEY L, GRANT JW, NORRIS PG: Imiquimod 5% cream in the treatment of mycosis fungoides - a pilot study./ Dermatolog Treat. (2004) 15(2):118–119.
   PubMedGoogle Scholar
• DUMMER R, HASSEL JC, FELLENBERG F et al.: Adenovirus-mediated intralesional interferon-gamma gene transfer induces tumor regressions in cutaneous lymphomas. Blood (2004) 104(6):1631–1638.
   PubMed Web of Science ®Google Scholar
• •First report on successful gene therapy approaches in primary CTCLs.
   Google Scholar
• MOTZER RJ, RAKHIT A. THOMPSON J et al.: Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma. Ann. Oncol (2002) 13(10:1799–1805.
   PubMed Web of Science ®Google Scholar
• BRUNDA MJ: Interleukin 12. J. Leukocyte Biol. (1994) 55(2):280–288.
   Google Scholar
• ROOK AH, ZAKI MH, WYSOCKA M et al.: The role for interleukin-12 therapy of cutaneous T cell lymphoma. Ann. NY Acad. Sci. (2001) 941:177–184.
   PubMed Web of Science ®Google Scholar
• TREFZER U, WALDEN P: Hybrid-cell vaccines for cancer immune therapy. MoL BiotechnoL (2003) 25(1):63–69.
   PubMed Web of Science ®Google Scholar
• MAIER T, TUN KYI A, TASSIS A et al.: Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood (2003) 102:2338–2344.
   PubMed Web of Science ®Google Scholar
• ZACKHEIM HS, KASHANI SABET M, AMIN S: Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch. DermatoL (1998) 134(8):949–954.
   PubMed Web of Science ®Google Scholar
• ZACKHEIM HS, EPSTEIN EJ, GRAIN WR: Topical carmustine (BCNU) for cutaneous T cell lymphoma: a 15-year experience in 143 patients. J. Am. Acad. Dermatol (1990) 22:802–810.
   PubMed Web of Science ®Google Scholar
• VONDERHEID EC, TAN ET, KANTOR AF, SHRAGER L, MICAILY B, VAN SCOTT EJ: Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J. Am. Acad. Dermatol (1989) 20(3):416–428.
   PubMed Web of Science ®Google Scholar
• HONIGSMANN H, BRENNER W, RAUSCHMEIER W, KONRAD K, WOLFF K: Photochemotherapy for cutaneous T cell lymphoma. A follow-up study. J. Am. Acad. Dermatol (1984) 10(2 Pt 1):238–245.
   PubMed Web of Science ®Google Scholar
• RAMSAY D1, LISH KM, YALOWITZ CB, SOTER NA: Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma. Arch. Dermatol (1992) 128(7):931–933.
   Google Scholar
• HOFER A, CERRONI L, KERL H, WOLF P: Narrowband (311-nM) UV-B therapy for small plaque parapsoriasis and early-stage mycosis fungoides. Arch. DermatoL (1999) 135(11):1377–1380.
   PubMed Web of Science ®Google Scholar
• CLARK C, DAWE RS, EVANS AT, LOWE G, FERGUSON J: Narrowband T1-01 phototherapy for patch-stage mycosis fungoides. Arch. Dermatol (2000) 136(6):748–752.
   PubMed Web of Science ®Google Scholar
• BRENEMAN D, DUVIC M, KUZEL T, YOCUM R, TRUGLIA J, STEVENS VJ: Phase I and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma. Arch. DermatoL (2002) 138(3):325–332.
   PubMed Web of Science ®Google Scholar
• DUMMER R, KRASOVEC M, ROGER J, SINDERMANN H, BURG G: Topical application of hexadecylphosphocholine in patients with cutaneous lymphomas: results of a Phase I/II study. J. American Acad. Dermatol (1993) 29(12):963–970.
   Google Scholar
• HODAK E, PHENIG E, AMICHAI B et al.: Unilesional mycosis fungoides: a study of seven cases. Dermatology (2000) 201(4):300–306.
   PubMed Web of Science ®Google Scholar
• HEALD PW, GLUSAC EJ: Unilesional cutaneous T-cell lymphoma: clinical features, therapy, and follow-up of 10 patients with a treatment-responsive mycosis fungoides variant. J. Am. Acad. DermatoL (2000) 42(2 Pt 1):283–285.
   PubMed Web of Science ®Google Scholar
• GOLDSCHMIDT H: Radiation therapy of other cutaneous tumors. In: Modern dermatologic radiation therapy. Goldschmidt H, Panizzon R (Eds), Springer Verlag, New York, Inc., Heidelberg, Berlin, Germany (1991):123–132.
   Google Scholar
• CERRONI L, FINK PUCHES R, EL SHABRAWI CAELEN L, SOYER HP, LEBOIT PE, KERL H: Solitary skin lesions with histopathologic features of early mycosis fungoides. Am. J. Dermatopathol (1999) 21(6):518–524.
   PubMed Web of Science ®Google Scholar
• RAJAN G, SEIFERT B, PROMMER O, JOLLER-JEMELKA H, BURG G, DUMMER R: Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon-alpha 2a combined with acetretin or puva. Arch. Derm. Res. (1996) 288: 543–548.
   Google Scholar
• STADLER R, OTTE HG, LUGER T et al: Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus puva in patients with cutaneous T-cell lymphoma stages land II. Blood (1998) 92(10):3578–3581.
   PubMed Web of Science ®Google Scholar
• •Prospective randomised trial.
   Google Scholar
• KUZEL TM, ROENIGK HH Jr, SAMUELSON E et al.: Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sezary syndrome. J. Clin. Oncol. (1995) 13(1):257–263.
   PubMed Web of Science ®Google Scholar
• ROENIGK H, KUZEL TM, SKOUTELIS AP et al.: Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J. Invest. Dermatol (1990) 95:S198–S205.
   Web of Science ®Google Scholar
• ZACKHEIM HS, KASHANI SABET M, MCMILLAN A: Low-dose methotrexate to treat mycosis fitngoides: a retrospective study in 69 patients. J. Am. Acad. Dermatol (2003) 49(5):873–878.
   PubMed Web of Science ®Google Scholar
• KIROVA YM, PIEDBOIS Y, PAN Q, GUO L, LE BOURGEOIS JP: Radiotherapie des lymphomes cutanes. Cancer Radiother. (1999) 3(2):105–111.
   PubMedGoogle Scholar
• FRASER ANDREWS E, SEED P, WHITTAKER S, RUSSELL JONES R: Extracorporeal photopheresis in Sezary syndrome. No significant effect in the survival of 44 patients with a peripheral blood T-cell clone. Arch. Dermatol (1998) 134(8): 1001–1005.
   PubMed Web of Science ®Google Scholar
• HEALD P, ROOK A, PEREZ M et al: Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J. Am. Acad. Dermatol (1992) 27(3):427–433.
   PubMed Web of Science ®Google Scholar
• KNOBLER R, GIRARDI M: Extracorporeal photochemoimmunotherapy in cutaneous T cell lymphomas. Ann. NY Acad. Sci. (2001) 941:123–138.
   PubMed Web of Science ®Google Scholar
• RUSSELL JONES R: Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline the need for randomized studies. Br. J. Dermatol (2000) 142(1):16–21.
   PubMed Web of Science ®Google Scholar
• STEVENS SR, BOWEN GM, DUVIC M et al: Effectiveness of photopheresis in Sezary syndrome. Arch. DermatoL (1999) 135(8):995–997.
   PubMed Web of Science ®Google Scholar
• CHINN DM, CHOW S, KIM YH, HOPPE RT: Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int. J. Radiat. OncoL Biol. Phys. (1999) 43(5):951–958.
   PubMed Web of Science ®Google Scholar
• JONES GW, ROSENTHAL D, WILSON LD: Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the Sezary syndrome). Cancer (1999) 85(9):1985–1995.
   PubMed Web of Science ®Google Scholar
• COORS EA, VON DEN DRIESCH P: Treatment of erythrodermic cutaneous T-cell lymphoma with intermittent chlorambucil and fluocortolone therapy. Br. J. DermatoL (2000) 143(1):127–131.
   PubMed Web of Science ®Google Scholar
• BUNN PJ, HOFFMAN SJ, NORRIS D, GOLITZ LE, AELING JL: Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sezary syndrome). Ann. Intern. Med. (1994) 121(8):592–602.
   PubMed Web of Science ®Google Scholar
• FIERRO MT, QUAGLINO P, SAVOIA P, VERRONE A, BERNENGO MG: Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP. Leuk. Lymphoma (1998) 31(5-0:583–588.
   PubMed Web of Science ®Google Scholar
• KUZEL TM, HURRIA A, SAMUELSON E et al.: Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood (1996) 87(3):906–911.
   PubMed Web of Science ®Google Scholar